Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer (LERFOX-C)
A Phase II Study With Oxaliplatin + 5-FU + Ceuximab and Radiotherapy for the Treatment of Non-resectable, Locally Advanced But Not Metastatic Cancer of Oesophagus or the Cardia.
研究概览
详细说明
Patients are treated with three cycles of oxaliplatin and fluorouracil 750 mg/m2/24 hours, day 1-5. Each cycle lasts for 21 days. Oxaliplatin is given with 130 mg/m2 in the first cycle and in cycle 2 and 3 which are administered concomitant with radiotherapy the dose is reduced to 85 mg/m2.
A loading dose of cetuximab 400 mg/m2 is given one week before the start of radiotherapy, and thereafter 250 mg/m2 is given weekly during the course of radiotherapy.
Concomitant with chemotherapy radiotherapy to a total dose of 50 Gy is given (2 Gy once daily in 25 fractions, 5 days a week) with a photon beam linear accelerator.
After treatment patients are followed every 6 months for three years with clinical examination and a CT-scan.
研究类型
注册 (实际的)
阶段
- 阶段2
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
Inclusion Criteria:
- Histological verified squamos cell carcinoma or adenocarcinoma of the oesophagus or cardia
- Performance status WHO 0-2, age 18-75 years
- Locally advanced disease, non-resectable (T4 N0-N3 M0) or disease which is not operable for any other reason (T2/T3 N0-N3 M0)
- Adequate hematological, liver and renal function
- Written informed consent
Exclusion Criteria:
- Distant metastases
- Prior chemotherapy or radiotherapy for oesophageal cancer or cancer of the cardia
- Symptomatic peripheral neuropathy equal to or greater than NCI grade 2
- Other concomitant serious illness or medical condition that would not permit the patient to complete the study treatment or sign the informed consent
- Myocardial infarction within 6 months prior to study entry
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) unless treated, in remission and off active treatment for greater than 2 years
- Pregnancy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Cetuximab
Cetuximab is administered once a week.
The initial dose is 400 mg/m2 body surface area.
First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Local tumour Control
大体时间:1 year
|
Local tumour control will be measured with a computed tomography
|
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression-free survival
大体时间:3 years
|
Tumour respons evaluation with CT-scan
|
3 years
|
Toxicity
大体时间:3 years
|
Toxicity will be measured with the Common Toxicity Criteria Scale
|
3 years
|
Patterns of relapse
大体时间:3 years
|
First site of recurrence will be evaluated with CT, supplemented with biopsy if indicated
|
3 years
|
Overall and disease-free survival
大体时间:3 years
|
Tumour respons evaluation with CT scan
|
3 years
|
Quality of life
大体时间:3 years
|
Quality of life assessed with the EORTC QLQ-C30 questionnaire.
|
3 years
|
合作者和调查者
调查人员
- 首席研究员:Gabriella A von Döbeln, MD、Karolinska University Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
西妥昔单抗的临床试验
-
Pfizer招聘中实体瘤美国, 西班牙, 加拿大, 意大利, 澳大利亚, 匈牙利, 荷兰, 英国, 德国, 巴西, 大韩民国, 葡萄牙, 法国, 日本, 以色列, 斯洛伐克, 捷克语